You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
|
|---|---|
| Published in |
Frontiers in Neurology, August 2015
|
| DOI | 10.3389/fneur.2015.00177 |
| Pubmed ID | |
| Authors |
Lars Wojtecki, Stefan J. Groiss, Stefano Ferrea, Saskia Elben, Christian J. Hartmann, Stephen B. Dunnett, Anne Rosser, Carsten Saft, Martin Südmeyer, Christian Ohmann, Alfons Schnitzler, Jan Vesper, for the Surgical Approaches Working Group of the European Huntington’s Disease Network |
| Abstract |
Movement disorders in Huntington's disease are often medically refractive. The aim of the trial was assessment of procedure safety of deep brain stimulation, equality of internal- and external-pallidal stimulation and efficacy followed-up for 6 months in a prospective pilot trial. In a controlled double-blind phase six patients (four chorea-dominant, two Westphal-variant) with predominant movement disorder were randomly assigned to either the sequence of 6-week internal- or 6-week external-pallidal stimulation, or vice versa, followed by further 3 months chronic pallidal stimulation at the target with best effect-side-effect ratio. Primary endpoints were changes in the Unified Huntington's Disease Rating Scale motor-score, chorea subscore, and total motor-score 4 (blinded-video ratings), comparing internal- versus external-pallidal stimulation, and 6 months versus baseline. Secondary endpoints assessed scores on dystonia, hypokinesia, cognition, mood, functionality/disability, and quality-of-life. Intention-to-treat analysis of all patients (n = 3 in each treatment sequence): Both targets were equal in terms of efficacy. Chorea subscores decreased significantly over 6 months (-5.3 (60.2%), p = 0.037). Effects on dystonia were not significant over the group due to it consisting of three responders (>50% improvement) and three non-responders. Westphal patients did not improve. Cognition was stable. Mood and some functionality/disability and quality-of-life scores improved significantly. Eight adverse events and two additional serious adverse events - mostly internal-pallidal stimulation-related - resolved without sequalae. No procedure-related complications occurred. Pallidal deep brain stimulation was demonstrated to be a safe treatment option for the reduction of chorea in Huntington's disease. Their effects on chorea and dystonia and on quality-of-life should be examined in larger controlled trials. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 38% |
| France | 1 | 13% |
| Switzerland | 1 | 13% |
| Chile | 1 | 13% |
| Ireland | 1 | 13% |
| Germany | 1 | 13% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 38% |
| Practitioners (doctors, other healthcare professionals) | 2 | 25% |
| Science communicators (journalists, bloggers, editors) | 2 | 25% |
| Scientists | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 3 | 3% |
| Russia | 1 | 1% |
| United Kingdom | 1 | 1% |
| Unknown | 85 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 19% |
| Student > Bachelor | 16 | 18% |
| Student > Ph. D. Student | 10 | 11% |
| Student > Doctoral Student | 7 | 8% |
| Other | 7 | 8% |
| Other | 15 | 17% |
| Unknown | 18 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 27% |
| Psychology | 12 | 13% |
| Neuroscience | 9 | 10% |
| Agricultural and Biological Sciences | 5 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Other | 11 | 12% |
| Unknown | 25 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2023.
All research outputs
#1,441,273
of 22,818,766 outputs
Outputs from Frontiers in Neurology
#492
of 11,701 outputs
Outputs of similar age
#20,574
of 266,174 outputs
Outputs of similar age from Frontiers in Neurology
#6
of 58 outputs
Altmetric has tracked 22,818,766 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,701 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,174 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.